Ivosidenib (Tibsovo®) monotherapy HTA ID: 23016

Assessment Status Rapid Review Complete
HTA ID 23016
Drug Ivosidenib
Brand Tibsovo®
Indication For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R 132 mutation who were previously treated by at least one prior line of systemic therapy
Assessment Process
Rapid review commissioned 08/03/2023
Rapid review completed 17/04/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ivosidenib compared with the current standard of care.